A groundbreaking discovery in the field of epilepsy treatment has emerged from clinical trials, offering a glimmer of hope for those battling this debilitating condition. The results are nothing short of revolutionary, especially for patients with Dravet syndrome, a severe form of epilepsy.
Led by Dr. Linda Laux, a renowned expert from Ann & Robert H. Lurie Children's Hospital of Chicago, these Phase 1/2a trials have demonstrated the safety and efficacy of a novel gene regulation treatment. Published in the esteemed New England Journal of Medicine, the findings reveal a significant reduction in seizures and improvements in various symptoms associated with Dravet syndrome, including language, motor, and behavioral issues.
But here's where it gets controversial... The treatment targets the root cause of Dravet syndrome, a mutation in the SCN1A gene, by acting on the normal gene to compensate for the mutated one. This innovative approach has led to unprecedented improvements in developmental and cognitive symptoms, a breakthrough in epilepsy management.
Dravet syndrome presents a spectrum of challenging symptoms that emerge in infancy and evolve over time. Most patients experience cognitive deficits, communication and behavioral impairments, motor dysfunction, growth delays, and autistic traits. Additionally, difficulties with feeding, poor appetite, and weight loss are common.
As Dr. Laux explains, patients with Dravet syndrome have a unique genetic makeup: a mutation on one SCN1A gene alongside a normal SCN1A gene. This mutation results in haploinsufficiency, where only half of the alpha 1 sodium receptor subunit is produced, leading to seizures and cognitive and motor issues. The study medication, zorevunersen, targets the normal SCN1A gene, enhancing its function to overcome the deficit caused by the mutated gene. Zorevunersen is administered via injection into the spinal fluid through a lumbar puncture.
One inspiring example is Owen, a 12-year-old boy with Dravet syndrome who participated in the clinical trial and is now continuing in the open-label extension study. Owen's seizures, previously uncontrolled by medications, have significantly reduced with zorevunersen. According to Dr. Laux, Owen has shown marked improvements in language and behavior. His mother, Austin, shares, "He is able to make friends, which is a new and wonderful development. His quality of life has improved so much that he can now enjoy activities with neurotypical peers."
The two Phase 1/2a, open-label, multicenter studies, conducted in the U.S. and the U.K., enrolled 81 patients with Dravet syndrome aged 2–18 years who were on standard antiseizure medications. Patients who received two to three doses of 70 mg zorevunersen experienced a remarkable reduction in motor seizures, with nearly 85% reduction at three months and 73% at six months post-dosing.
Eligible patients, like Owen, transitioned to the open-label extension studies, where they received 45 mg of zorevunersen every four months. These patients continued to show significant seizure reduction, ranging from 58% to 90% over the first 20 months. For patients in the extension studies for more than 36 months, expressive and receptive communication skills significantly improved.
While nearly all patients experienced a treatment-emergent adverse event (TEAE), most were mild to moderate. The most common TEAE in the Phase 1/2a trials was post-lumbar puncture syndrome (nearly 25%), while the most common event in the extension studies was an increase in cerebrospinal fluid (CSF) protein (45%). Importantly, none of the patients with CSF protein increase experienced increased intracranial pressure or hydrocephalus. Of the serious TEAEs, only one was considered treatment-related.
Dr. Laux emphasizes, "Our data support the safety and tolerability of zorevunersen, as well as improvements in overall clinical status, quality of life, and adaptive behavior following continued dosing in the extension studies."
A Phase 3, double-blind, placebo-controlled trial of zorevunersen for Dravet syndrome is currently underway, further solidifying the potential of this groundbreaking treatment.
The funding for these trials was provided by Stoke Therapeutics, and Dr. Laux holds the prestigious Lorna S. and James P. Langdon Chair in Pediatric Neurology at Lurie Children's.
Ann & Robert H. Lurie Children's Hospital of Chicago is a nonprofit organization dedicated to providing exceptional care to every child. As the only independent, research-driven children's hospital in Illinois and one of less than 35 nationally, it attracts top doctors for training, pediatric medicine practice, teaching, advocacy, research, and staying updated on the latest treatments. Exclusively focused on children, all Lurie Children's resources are dedicated to meeting their unique needs.
